Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: A retrospective case-control study.
COVID-19
RT-PCR
corticosteroids
cycle threshold
viral load
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
04
12
2021
received:
23
10
2021
accepted:
16
01
2022
pubmed:
20
1
2022
medline:
24
3
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Remdesivir is a broad-spectrum antiviral agent able to inhibit the RNA polymerase of SARS-CoV-2. At present, studies focusing on the effect of remdesivir on viral load (VL) are few and with contrasting results. Aim of the present study was to evaluate the effect of remdesivir on SARS-CoV-2 VL from nasopharyngeal swabs (cycle threshold criterion) in a sample of patients treated with the drug, compared with patients who did not receive the antiviral treatment. This retrospective analysis evaluated patients with (1) real-time polymerase chain reaction (RT-PCR) confirmed COVID-19 diagnosis and (2) availability of at least two positive nasopharyngeal swabs analysed with the same analytic platform (ORF target gene, Ingenius ELITe, ELITechGroup, Puteaux, France). Upper respiratory specimens from nasopharyngeal swabs were collected at admission (T0) and 7-14 days after treatment, upon clinical decision. A total of 27 patients treated with remdesivir (Group A) met the inclusion criteria and were compared with 18 patients (Group B) treated with standard care, matched for baseline clinical characteristics. At baseline, both remdesivir-treated and nontreated patients showed comparable VLs (21.73 ± 6.81 vs. 19.27 ± 5.24, p = 0.348). At the second swab, remdesivir-treated patients showed a steeper VL reduction with respect to controls (34.28 ± 7.73 vs. 27.22 ± 3.92; p < 0.001). Longitudinal linear model estimated a mean decrease in cycle threshold equal to 0.61 (SE: 0.09) per day in remdesivir-treated versus 0.33 (SE: 0.10) per day in remdesivir nontreated patients (p for heterogeneity = 0.045). The present study shows that the administration of remdesivir in hospitalized COVID-19 patients significantly reduces the VL on nasopharyngeal swabs.
Identifiants
pubmed: 35043405
doi: 10.1002/jmv.27598
pmc: PMC9015337
doi:
Substances chimiques
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2284-2289Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Dölken L, Stich A, Spinner CD. Remdesivir for early COVID-19 treatment of high-risk individuals prior to or at early disease onset-lessons learned. Viruses. 2021;13:963. doi:10.3390/v13060963
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. doi:10.1016/j.lfs.2020.117477
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19-final report. N Engl J Med. 2020;383:1813-1826. doi:10.1056/NEJMoa2007764
Aleissa MM, Silverman EA, Paredes Acosta LM, Nutt CT, Richterman A, Marty FM. New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrob Agents Chemother. 2020;65:e01814-e01820. doi:10.1128/AAC.01814-20
Garibaldi BT, Wang K, Robinson ML, et al. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw Open. 2021;4:e213071. doi:10.1001/jamanetworkopen.2021.3071.
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-1578. doi:10.1016/S0140-6736(20)31022-9
Gastine S, Pang J, Boshier FAT, et al. Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies. Clin Pharmacol Ther. 2021;110:2223-2333. doi:10.1002/cpt.2223
WHO Solidarity Trial Consortium, WHO Solidarity Trial C, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19-Interim WHO Solidarity Trial Results. N Engl J Med. 2020;384:497-511. doi:10.1056/NEJMoa2023184
Joo EJ, Ko JH, Kim SE, et al. Clinical and virologic effectiveness of remdesivir treatment for severe coronavirus disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. J Korean Med Sci. 2021;36:e83. doi:10.3346/jkms.2021.36.e83
Pawar RD, Balaji L, Mehta S, et al. Viral load and disease severity in COVID-19. Intern Emerg Med Jun. 2021;16:1-9. doi:10.1007/s11739-021-02786-w
Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493. doi:10.1038/s41467-020-19057-5
Goldberg E, Ben Zvi H, Sheena L, et al. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. Clin Microbiol Infect. 2021;27(917):e1-917. doi:10.1016/j.cmi.2021.02.029.e4
Regan J, Flynn JP, Rosenthal A, et al. Viral load kinetics of severe acute respiratory syndrome coronavirus 2 in hospitalized individuals with coronavirus disease 2019. Open Forum Infect Dis. 2021;8:53.
Ziegler K, Steininger P, Ziegler R, Steinmann J, Korn K, Ensser A. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045. doi:10.2807/1560-7917.ES.2020.25.39.2001650
https://www.elitechgroup.com/wp-content/uploads/sites/16/2020/06/SCH-mRTS170ING_08_en-1.pdf
Dubert M, Visseaux B, Isernia V, et al. Case report study of the first five COVID-19 patients treated with remdesivir in France. Int J Infect Dis. 2020;98:290-293.
Wong CKH, Lau KTK, Au ICH, Xiong X, Lau EHY, Cowling BJ. Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19. Clin Infect Dis. 2021:ciab631. Forthcoming. doi:10.1093/cid/ciab631
Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial. Ann Intern Med. 2021;174:1261-1269.
Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 2020;34:1241-1243. doi:10.23812/20-EDITORIAL_1-5
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, WHO Rapid Evidence Appraisal for COVID- Therapies (REACT) Working G, Sterne J, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330-1341. doi:10.1001/jama.2020.17023
Vecchié A, Batticciotto A, Tangianu F, et al. High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. Intern Emerg Med Jul. 2021;16:1913-1919. doi:10.1007/s11739-021-02800-1
Mirijello A, Piscitelli P, de Matthaeis A, et al. Low eGFR is a strong predictor of worse outcome in hospitalized COVID-19 patients. J Clin Med. 2021;10(22):5224.
Piccica M, Lagi F, Trotta M, Spinicci M, Zammarchi L, Bartoloni A, COCORA Working Group. High-dose steroids for the treatment of severe COVID-19. Intern Emerg Med. 2021;15:1-5. doi:10.1007/s11739-021-02707-x